This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Biocryst Pharmaceuticals, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: The Innovations of Viral Kansara in Ophthalmic Therapies.
Introduction
Viral Kansara is an accomplished inventor based in Alpharetta, GA (US). He has made significant contributions to the field of ophthalmic therapies, particularly in the treatment of ocular disorders. His innovative work focuses on non-surgical methods for administering drug compositions that contain plasma kallikrein inhibitors.
Latest Patents
Viral Kansara holds a patent for "Plasma kallikrein inhibitors and methods of use thereof in ocular disorders." This patent addresses the treatment of various ocular diseases and conditions through the delivery of a plasma kallikrein inhibitor to the suprachoroidal space (SCS) of the eye. The patent highlights the use of avoralstat as a plasma kallikrein inhibitor, showcasing a novel approach to ocular therapy.
Career Highlights
Viral Kansara is currently associated with Biocryst Pharmaceuticals, Inc., where he continues to advance his research in ophthalmic treatments. His work has the potential to significantly impact the way ocular disorders are treated, providing new avenues for patient care.
Collaborations
Viral collaborates with Rick McElheny, leveraging their combined expertise to further enhance the development of innovative therapies in the field of ophthalmology.
Conclusion
Viral Kansara's contributions to ophthalmic therapies through his patent on plasma kallikrein inhibitors exemplify the importance of innovation in medical treatments. His work at Biocryst Pharmaceuticals, Inc. continues to pave the way for advancements in ocular health.